Bionano Genomics vs Maxcyte
Maxcyte is the larger business, with $33.0m of revenue in fiscal 2025 against $28.5m for Bionano Genomics (1.2 times as much). Bionano Genomics grew faster (-7.4% against -14.5%). Bionano Genomics kept more of each dollar of sales as profit: a net margin of -92.6% against -135.1%. Bionano Genomics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Bionano GenomicsBNGO, 2025 | MaxcyteMXCT, 2025 |
|---|---|---|
| Revenue | $28.5m | $33.0m |
| Revenue growth | -7.4% | -14.5% |
| Net income | −$26.4m | −$44.6m |
| Operating margin | -116.9% | -157.1% |
| Net margin | -92.6% | -135.1% |
| Return on equity | -66.2% | -23.6% |
| Free cash flow | −$16.3m | −$36.2m |
| Cash | $3.0m | $20.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 97 | 91 |
| Market value | $14.1m | $150m |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | 30 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 0 buys, 1 sales |